News

Cristiano Ronaldo investment helps raise the stakes for personalised nutrition player Bioniq

Cristiano Ronaldo has invested $15 million in personalised nutrition company Bioniq, a move that not only raises the value of the company to $82 million, but also kickstarts its marketing and branding efforts.

The UK-based company has made a name for itself by using blood biomarker data to provide highly targeted nutritional support products. Football legend Ronaldo has been a Bioniq customer for the past three years. His highly successful and unusually long-lasting international football career gives the endorsement added impetus. Bioniq wants to spread the message that optimised nutrition can help both high performance athletes and other consumers.

The investment takes Bioniq to the next stage of development

Bioniq was founded in 2019, and the company’s products are now sold in over 70 countries worldwide. That growth has seen a significant spike in 2024, with the company claiming that its consumer base has grown five-fold since the beginning of the year.

Ronaldo’s investment in the company should serve to capitalise on this bounce, helping to spread the word about the company’s customised supplements, which are gaining in popularity thanks to its novel take on health and nutrition.

“Cristiano Ronaldo’s investment and partnership certify Bioniq’s ability to provide pharmaceutical-grade nutritional supplements to top performers and health-minded consumers alike. Bioniq’s recent funding will focus on product development including global laboratory network integrations, market, operational, and human resources expansion in the U.S. and the Middle East,” said Bioniq's CEO Vadim Fedotov.

What Bioniq is doing to differentiate itself

While the personalised nutrition space remains niche and underexplored, it is growing fast, with a raft of new players hitting the market recently. Fedotov believes that where Bioniq has the edge is the company proprietary biochemical database, which is the largest of its kind.

“Bioniq leverages data from customers across five continents alongside an AI-powered algorithm to assess an individual's height, weight, age, lifestyle and health goals to create our tailored, pharmaceutical-grade formulas. Our AI amalgamates and assesses clinical research, international regulatory and nutritional considerations, and individuals’ specific goals and unique needs to provide a bespoke formulation in line with the latest clinical research and dosing guidelines,” Fedotov said.

All of the company’s formulations are made in Switzerland and can contain up to 120 nutrients. Each product is individually manufactured according to blood biomarkers, BMI and health goals that determine what the specific nutritional requirements are. The service also includes 1:1 nutritional guidance to help individuals achieve their health goals. Its existing product line consists of Bioniq GO, a line developed for personal daily supplementation, and Bioniq Pro, which targets highest level performance needs.

“Rather than multiple capsules and pills, we use patented prebiotic guar granules which are designed to mimic the way the body digests food, minimizing nutrient competition, maximizing bioavailability, and ensuring sustained release and precise micro-dosing to address bio-individual micronutrient needs and deficiencies. Our ability to provide quantifiable before-and-after snapshots of users’ nutrient needs and optimization progress sets us apart from others in the space,” Fedotov said.

Bioniq’s longer-term goals are further expansion

While the company has grown fast in the past couple of years, it is aiming to further expand its footing in the personalised nutrition market, particularly with an emphasis on growing its existing geographic footprint by attracting further investment.

“Bioniq is focused on expanding its presence globally and bringing both its Bioniq GO and Bioniq PRO offerings to users in more than 70 countries. We continue to partner with high-caliber individuals and organizations and plan to implement a corporate platform for medical, wellness, and athletic institutions in the coming years. Depending on the market, we may look to future fundraises in the coming years,” said Fedotov.